518 related articles for article (PubMed ID: 10856105)
1. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
3. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
4. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
5. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
6. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
Rao UN; Ibrahim J; Flaherty LE; Richards J; Kirkwood JM
J Clin Oncol; 2002 Apr; 20(8):2053-7. PubMed ID: 11956265
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
[TBL] [Abstract][Full Text] [Related]
8. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H
J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440
[TBL] [Abstract][Full Text] [Related]
10. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
Kilbridge KL; Cole BF; Kirkwood JM; Haluska FG; Atkins MA; Ruckdeschel JC; Sock DE; Nease RF; Weeks JC
J Clin Oncol; 2002 Mar; 20(5):1311-8. PubMed ID: 11870174
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB; Legha SS; Gonzalez R; Anderson CM; Johnson MM; Liu P; Papadopoulos NE; Eton O; Plager C; Buzaid AC; Prieto VG; Hwu WJ; Frost AM; Alvarado G; Hwu P; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Benjamin RS; Bedikian AY
Melanoma Res; 2009 Feb; 19(1):42-9. PubMed ID: 19430405
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Therapy for Melanoma.
Agha A; Tarhini AA
Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
18. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
19. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
20. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]